title: [Host immunity in colorectal cancer patients treated with TS-1 plus CPT-11].
abstract: TS-1/CPT-11 treatment for the patients with advanced colorectal cancer is expected to be equal to FOLFOX and FOLFIRI regimen. The aim of this study was to investigate the relationship between host immunity and this regimen. Four patients were enrolled in this study. Host immunity was investigated before and after chemotherapy. PHA response, serum IAP level and the productions of any cytokines did not change significantly before and after the chemotherapy. Although these changes were not significant: both Th1/Th2 ratio and NK cells ratio were decreased, and the ratio of suppressor T cells was increased. These results suggest that TS-1/CPT-11 regimen may influence host immunity a little bit worse.
authors.affiliation: Dept. of Surgery, Tokyo Women's Medical University Daini Hospital.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshimatsu
authors.forename: Rie
authors.initials: R
authors.lastname: Kobayashi
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Hajime
authors.initials: H
authors.lastname: Yokomizo
authors.forename: Masaki
authors.initials: M
authors.lastname: Aizawa
authors.forename: Hiroko
authors.initials: H
authors.lastname: Itagaki
authors.forename: Takao
authors.initials: T
authors.lastname: Katsube
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Naritaka
authors.forename: Kenji
authors.initials: K
authors.lastname: Ogawa
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077146:Irinotecan; D017640:Silicates / Q000008:administration & dosage*; D014025:Titanium / Q000008:administration & dosage*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017640:Silicates; C103828:titanium silicide; D000077146:Irinotecan; D014025:Titanium; D002166:Camptothecin